Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
This trial is active, not recruiting.
|Condition||chronic lymphocytic leukemia|
|Sponsor||Acerta Pharma BV|
|Start date||August 2014|
|End date||September 2018|
|Trial size||12 participants|
|Trial identifier||NCT02157324, ACE-CL-002|
This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia (CLL)
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Columbus, OH||not available||no longer recruiting|
|Columbus, OH||Ohio State University Comprehensive Cancer Center||no longer recruiting|
|Houston, TX||not available||no longer recruiting|
|Houston, TX||M D Anderson Cancer Center||no longer recruiting|
|Endpoint classification||safety/efficacy study|
|Intervention model||parallel assignment|
Starts with acalabrutinib for 7 days, then combined with ACP-319 afterwards.
Starts with ACP-319 for 7 days, then combined with acalabrutinib afterwards.
Characterize the pharmacokinetics of acalabrutinib and ACP-319
time frame: Cycle 1 (28 Days)
Male or female participants at least 18 years old.
- Men and women ≥ 18 years of age with a confirmed diagnosis of CLL, which has relapsed after, or been refractory to, ≥ 1 previous treatments for CLL; however, subjects with 17p deletion are eligible if they have relapsed after, or been refractory to, 1 prior treatment for CLL.
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
- Agreement to use contraception during the study and for 30 days after the last dose of study drugs if sexually active and able to bear or beget children.
- Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to < 2 years.
- A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acalabrutinib and/or ACP-319, or put the study outcomes at undue risk.
- Significant cardiovascular disease.
- Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
- Any immunotherapy within 4 weeks of first dose of study drug.
- For subjects with recent chemotherapy or experimental therapy the first dose of study drug must occur after 5 times the half-life of the agent(s).
- History of prior allogeneic bone marrow progenitor cell or solid organ transplantation.
- Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids for treatment of CLL or other conditions. Note: Subjects may be using topical or inhaled corticosteroids as therapy for comorbid conditions.
- Central nervous system (CNS) involvement by CLL.
- Grade ≥ 2 toxicity (other than alopecia).
- Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) or any uncontrolled active systemic infection.
- Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura.
- Absolute neutrophil count (ANC) < 0.75 x 109/L or platelet count < 50 x 109/L unless due to disease involvement in the bone marrow.
- Creatinine > 1.5 x institutional upper limit of normal (ULN); total bilirubin > 1.5 x ULN (unless due to Gilbert's disease); and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x ULN unless disease related.
- Significant screening ECG abnormalities including left bundle branch block, 2nd degree AV block type II, 3rd degree block, Grade 2 or higher bradycardia, and QTc > 480 msec.
|Official title||A Multicenter, Open-label, Phase 1 Pilot Study of ACP-196 in Combination With ACP-319 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia|
Call for more information